论文部分内容阅读
目的探讨单用伊马替尼及其联合干扰素-α(interferon-α,IFN-α)治疗慢性髓性白血病(chronic myelognous leukemia,CML)的效果。方法选取2011年1月—2013年1月医院收治的CML患者84例作为研究对象,根据治疗方案随机将患者分为两组,口服伊马替尼400 mg/d治疗作为A组,口服400 mg/d+IFN-α300万U皮下注射治疗作为B组,持续用药9个月,观察两组临床疗效及不良用药反应,对比观察两组患者完全血液学缓解(complete hematologic remission,CHR)、完全细胞遗传学缓解(complete cytogenetic remission,CCg R)、完全分子学缓解(commplete molecular remission,CMR)数量的发生率,随访1年记录生存率和死亡率,计量资料采用行χ2检验,P<0.05具有统计学意义。结果 B组CHR、CCg R、CMR的发生率分别为85.71%、69.05%、76.19%,均较A组(64.29%、45.24%、52.38%)高,差异均有统计学意义(均P<0.05);B组发热、脱发的发生率分别为61.90%、45.24%,均较A组(28.57%、4.76%)高,差异均有统计学意义(均P<0.05)。结论伊马替尼联合IFN-α治疗CML可提高临床疗效,但会增加不良用药反应。
Objective To investigate the effect of interferon-α (IFN-α) on chronic myelognous leukemia (CML) treated with imatinib alone. Methods Eighty-four CML patients admitted from January 2011 to January 2013 in our hospital were enrolled in this study. Patients were randomly divided into two groups according to the treatment regimen. Oral imatinib 400 mg / / d + IFN-α 3 million U subcutaneous injection as a group B, continuous medication for 9 months, the two groups were observed clinical efficacy and adverse drug reactions, the two groups were compared complete hematologic remission (complete hematologic remission, CHR), complete cells The incidence of complete cytogenetic remission (CCgR) and commplete molecular remission (CMR) was recorded. The survival rate and mortality were recorded after one year of follow-up. The measurement data were analyzed by Chi-square test. P <0.05 was statistically significant Significance of learning. Results The incidences of CHR, CCg R and CMR in group B were 85.71%, 69.05% and 76.19%, respectively, which were significantly higher than those in group A (64.29%, 45.24%, 52.38% ). The incidence of fever and alopecia in group B were 61.90% and 45.24% respectively, which were significantly higher than those in group A (28.57% and 4.76%, both P <0.05). Conclusion Imatinib combined with IFN-α in treatment of CML can improve the clinical curative effect, but it will increase the adverse drug reaction.